trending Market Intelligence /marketintelligence/en/news-insights/trending/XqY-TIZy0DudTS1jLKT9Vw2 content esgSubNav
In This List

Vernalis cough cold treatment rejected by US FDA

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Vernalis cough cold treatment rejected by US FDA

The U.S. Food and Drug Administration rejected Vernalis PLC's new drug application, or NDA, for its cough cold treatment CCP-08.

The company said items that resulted in a previous U.S. FDA rejection for a different cough cold treatment, CCP-07, were not addressed in time to avoid the same outcome for CCP-08.

Vernalis is working to resubmit NDAs for CCP-07 and CCP-08. Both treatments are products of a licensing and collaboration deal with Tris Pharma Inc. to develop cough cold treatments for the U.S. market.